Linden Capital snaps up Arsenal's BioIVT
The Chicago firm adds to an already busy year of healthcare dealmaking with an $800m-plus deal for the global provider of biological specimens and value-added services.
The Chicago firm adds to an already busy year of healthcare dealmaking with an $800m-plus deal for the global provider of biological specimens and value-added services.